Clin2
NCT06822868Possibly a fitRecruiting

Study of CT1190B for relapsed or refractory B-cell lymphoma

B-Cell Non-Hodgkin Lymphoma

Treatments studied

Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.

This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have been diagnosed with B-cell non-Hodgkin lymphoma and have tried at least two prior treatments.
  • Your last treatment did not work, stopped working, or caused side effects you could not tolerate.
  • You have measurable tumors (ones that can be seen on scans).
  • You are willing to use effective birth control for one year after the study treatment, and not donate eggs or sperm during that time.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07068906Not yet recruiting· Phase 1
Study of CT1194C for relapsed B-cell lymphoma

This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.

Tianjin
NCT06734871Recruiting· Phase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma

This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.

Shanghai, Shanghai Municipality
NCT07053670Recruiting· Phase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma

This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.

Wuhang, Hubei
NCT07032324Not yet recruiting· Phase 1
Experimental cell therapy for relapsed B-cell lymphoma

This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.

Hangzhou, Zhejiang
NCT07234045Not yet recruiting· Phase 1
Testing CT1195E for relapsed B-cell cancers

This trial is testing an investigational cell therapy called CT1195E for people with certain types of B-cell lymphoma or acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to see if CT1195E can help control the cancer.

Tianjin, Tianjin Municipality
NCT07200479Not yet recruiting· Phase 1
Immune cell therapy for B-cell lymphoma and leukemia

This clinical trial tests a new cell therapy, CT1194D, for people whose B-cell lymphoma (a type of blood cancer) or B-cell acute lymphoblastic leukemia has come back or is not responding to standard treatments. The goal is to see if this therapy can help shrink tumors or improve blood cell counts.

Tianjin

Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.